Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination

Dermatomyositis (DM) is one of the uncommon multi-organ idiopathic inflammatory myopathies that has been reported following the hepatitis B, Influenza, tetanus toxoid, H1N1, and BCG vaccines. However, an association with the coronavirus disease 2019 (COVID-19) vaccine is yet to be reported. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Gouda, Wesam, Albasri, Anwar, Alsaqabi, Faisal, Al Sabah, Humoud Y., Alkandari, Marwan, Abdelnaby, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822116/
https://www.ncbi.nlm.nih.gov/pubmed/35132838
http://dx.doi.org/10.3346/jkms.2022.37.e32
_version_ 1784646545433427968
author Gouda, Wesam
Albasri, Anwar
Alsaqabi, Faisal
Al Sabah, Humoud Y.
Alkandari, Marwan
Abdelnaby, Hassan
author_facet Gouda, Wesam
Albasri, Anwar
Alsaqabi, Faisal
Al Sabah, Humoud Y.
Alkandari, Marwan
Abdelnaby, Hassan
author_sort Gouda, Wesam
collection PubMed
description Dermatomyositis (DM) is one of the uncommon multi-organ idiopathic inflammatory myopathies that has been reported following the hepatitis B, Influenza, tetanus toxoid, H1N1, and BCG vaccines. However, an association with the coronavirus disease 2019 (COVID-19) vaccine is yet to be reported. In this case, we present the case of a 43-year-old Asian Indian female who was diagnosed with DM 10 days after receiving the second dosage of BNT162b2 mRNA COVID-19 vaccination, in the absence of any additional triggering factors. The diagnosis was established based on physical examination, serological antibodies, magnetic resonance imaging of the muscles, skin biopsy, and electromyography. She received standard treatment for DM, including oral high doses of prednisolone, hydroxychloroquine, mycophenolate, and physiotherapy. The treatment successfully reversed skin changes and muscle weakness. This is the first reported case of classic DM complicated by interstitial lung disease following COVID-19 vaccination. More clinical and functional studies are needed to elucidate this association. Clinicians should be aware of this unexpected adverse event following COVID-19 vaccination and arrange for appropriate management.
format Online
Article
Text
id pubmed-8822116
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean Academy of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-88221162022-02-15 Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination Gouda, Wesam Albasri, Anwar Alsaqabi, Faisal Al Sabah, Humoud Y. Alkandari, Marwan Abdelnaby, Hassan J Korean Med Sci Case Report Dermatomyositis (DM) is one of the uncommon multi-organ idiopathic inflammatory myopathies that has been reported following the hepatitis B, Influenza, tetanus toxoid, H1N1, and BCG vaccines. However, an association with the coronavirus disease 2019 (COVID-19) vaccine is yet to be reported. In this case, we present the case of a 43-year-old Asian Indian female who was diagnosed with DM 10 days after receiving the second dosage of BNT162b2 mRNA COVID-19 vaccination, in the absence of any additional triggering factors. The diagnosis was established based on physical examination, serological antibodies, magnetic resonance imaging of the muscles, skin biopsy, and electromyography. She received standard treatment for DM, including oral high doses of prednisolone, hydroxychloroquine, mycophenolate, and physiotherapy. The treatment successfully reversed skin changes and muscle weakness. This is the first reported case of classic DM complicated by interstitial lung disease following COVID-19 vaccination. More clinical and functional studies are needed to elucidate this association. Clinicians should be aware of this unexpected adverse event following COVID-19 vaccination and arrange for appropriate management. The Korean Academy of Medical Sciences 2022-01-07 /pmc/articles/PMC8822116/ /pubmed/35132838 http://dx.doi.org/10.3346/jkms.2022.37.e32 Text en © 2022 The Korean Academy of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Gouda, Wesam
Albasri, Anwar
Alsaqabi, Faisal
Al Sabah, Humoud Y.
Alkandari, Marwan
Abdelnaby, Hassan
Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
title Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
title_full Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
title_fullStr Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
title_full_unstemmed Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
title_short Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
title_sort dermatomyositis following bnt162b2 mrna covid-19 vaccination
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822116/
https://www.ncbi.nlm.nih.gov/pubmed/35132838
http://dx.doi.org/10.3346/jkms.2022.37.e32
work_keys_str_mv AT goudawesam dermatomyositisfollowingbnt162b2mrnacovid19vaccination
AT albasrianwar dermatomyositisfollowingbnt162b2mrnacovid19vaccination
AT alsaqabifaisal dermatomyositisfollowingbnt162b2mrnacovid19vaccination
AT alsabahhumoudy dermatomyositisfollowingbnt162b2mrnacovid19vaccination
AT alkandarimarwan dermatomyositisfollowingbnt162b2mrnacovid19vaccination
AT abdelnabyhassan dermatomyositisfollowingbnt162b2mrnacovid19vaccination